New BD® Research Cloud
provides scientists with an integrated ecosystem that allows for
optimizing panel design, collaboration and analysis
FRANKLIN
LAKES, N.J., Sept. 27,
2022 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
today launched BD® Research Cloud, a cloud-based software solution
designed to streamline the flow cytometry workflow to enable higher
quality experiments with faster time to insight for scientists
working across a range of disciplines including immunology,
virology, oncology and infectious disease monitoring.
![BD® Research Cloud is a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines. BD® Research Cloud is a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines.](https://mma.prnewswire.com/media/1907748/BD_RC_Reagent_Selector.jpg)
Flow cytometry is an essential tool used to analyze single cells
based on their characteristics, letting scientists study them in
more detail to better understand health and disease. Traditional
flow cytometry workflows can be inefficient, time consuming and
involve many incompatible systems. BD® Research Cloud, developed by
the BD software engineers who created FlowJo™ Software, bridges and
integrates all of the flow cytometry workflow steps, enabling
scientists to more easily design reagent panels, connect
instruments with data analysis software, store experimental data
and procedures, and manage collaboration with colleagues.
"The modern flow cytometry lab can be busy with limited staff,
which is why making experiments more organized, more efficient,
along with making the data more easily accessible in the future, is
of extreme value," said David
Archer, PhD, whose research interests are focused on the
pathogenesis of sickle cell disease. "A cloud software solution
that can support researchers from the panel design process to
easily ordering those reagents to then defining the experiment to
run on a flow cytometer, is a valuable tool and has the potential
to accelerate time to discovery and publication."
BD® Research Cloud is built on an industry-standard cloud
infrastructure and is specially optimized for BD instruments and
reagents. As a cloud-based open system, future releases will
provide users with even more intuitive and powerful capabilities,
alongside growing resources from BD including panel design
education sessions, e-books and dedicated applications support.
"BD is committed to delivering innovative solutions to our
customers that enhance the quality and efficiency of their flow
cytometry research in new and meaningful ways," said Steve Conly, newly appointed worldwide president
of BD Biosciences. "BD® Research Cloud is a powerful all-in-one
platform that connects instruments, reagents and data analysis,
bringing more complex experiments within reach — which can aid and
propel potentially life-changing research from discovery to drug
development. In combination with other BD innovations, including
our new BD Horizon RealYellow™ and RealBlue™ Reagents and newly
unveiled BD FACSDiscover™ S8 Cell Sorter with BD CellView™ Image
Technology, BD is unlocking new potential for flow cytometry to
optimize and advance groundbreaking research."
For more information about BD® Research Cloud, visit
bdbiosciences.com/bdresearchcloud.
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health™ by improving
medical discovery, diagnostics and the delivery of care. The
company supports the heroes on the frontlines of health care by
developing innovative technology, services and solutions that help
advance both clinical therapy for patients and clinical process for
health care providers. BD and its 75,000 employees have a passion
and commitment to help enhance the safety and efficiency of
clinicians' care delivery process, enable laboratory scientists to
accurately detect disease and advance researchers' capabilities to
develop the next generation of diagnostics and therapeutics. BD has
a presence in virtually every country and partners with
organizations around the world to address some of the most
challenging global health issues. By working in close collaboration
with customers, BD can help enhance outcomes, lower costs, increase
efficiencies, improve safety and expand access to health care. For
more information on BD, please visit bd.com or connect with us on
LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
|
|
Media:
|
Investors:
|
|
|
Troy Kirkpatrick
|
Francesca
DeMartino
|
VP, Public
Relations
|
SVP, Head of Investor
Relations
|
858.617.2361
|
201.847.5743
|
troy.kirkpatrick@bd.com
|
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-launches-state-of-the-art-cloud-software-solution-to-streamline-flow-cytometry-research-301633392.html
SOURCE BD (Becton, Dickinson and Company)